ClinicalTrials.gg
Active, not recruitingNCT05010590Updated Apr 15, 2026

Anabolic Therapy in Postmenopausal Osteoporosis

A Phase 4 interventional study of Romosozumab and Denosumab in Postmenopausal Osteoporosis, sponsored by Massachusetts General Hospital. Active, not recruiting at 1 site in United States. Open to female participants aged 45 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Massachusetts General Hospital · Phase 4, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
45 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies testing denosumab in Osteoporosis, Postmenopausal — 1 open to participants now, 3 under way, 2 of them phase 3. Denosumab · Osteoporosis, Postmenopausal.

Enrollment
27th of 31
50 · median 278
Started
2022
with 1 other
Phase 4
8 of 31
none open now
Registered
27th of 31
by date
Lead sponsor
4 of 31
Massachusetts General Hospital

Among the 31 studies testing denosumab in Osteoporosis, Postmenopausal, this one is the 27th largest by enrollment, is one of 2 that started in 2022, is one of 8 in phase 4, and was the 27th registered.

Osteoporosis, Postmenopausal

334 studies on the registry are indexed under Osteoporosis, Postmenopausal; 28 are open to participants now.

Browse Osteoporosis, Postmenopausal studies →

Open to participants now

1 of the 31 studies testing denosumab in Osteoporosis, Postmenopausal is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Osteoporosis, Postmenopausal studies recruiting now, 8 (40%) set no upper age limit and 8 (40%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 45 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing denosumab in Osteoporosis, Postmenopausal, or all of them as a file.
02

Study summary

In this research study we want to learn more about the effect of two different FDA-approved medications in the treatment of osteoporosis.

03

Conditions studied

  • Postmenopausal Osteoporosis
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women at high risk of fracture

Exclusion criteria

Exclusion Criteria:

  • Prior therapy exclusions

    1. current use or use in the past 12 months of oral bisphosphonates or denosumab
    2. current use or use within the past 3 months of estrogens, SERMs, or calcitonin.
    3. use of oral or parenteral for more than 14 days within the past 6 months
    4. any current or previous use of romosozumab or strontium
    5. current use or use within the past 3 years of teriparatide, abaloparatide, or any parenteral bisphosphonate.

Other exclusions

  1. Confirmed serum alkaline greater than 2 times the upper normal limit.
  2. Stage 4 or 5 chronic kidney disease ( less than 30)
  3. Hypercalcemia (Ca greater than 10.5 mg/dL)
  4. Hypocalcemia (Ca less than 8.8 mg/dL)
  5. Elevated blood PTH (intact PTH greater than 77 pg/mL)
  6. Serum 25-OH vitamin D less than 20 ng/mL
  7. HCT less than 32%.
  8. History of (except basal cell carcinoma).
  9. Significant pulmonary disease
  10. History of myocardial infarction or stroke within the preceding year.
  11. History of unstable angina or in the past year.
  12. Current atrial fibrillation.
  13. Any health condition that, in the opinion of the study physician, significantly increases the risk of cardiovascular events.
  14. Major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate or completing the protocol procedures.
  15. Excessive alcohol use or substance abuse that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
  16. Uncontrolled eczema
  17. Congenital or acquired bone disease other than osteoporosis.
  18. Known sensitivity to denosumab or any of its .
  19. Known sensitivity to romosozumab or any of its excipients.
  20. History of osteonecrosis of the jaw, extensive dental work involving extraction or dental implants in the past 3 months, or extensive dental work planned in the upcoming 12 months.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Romosozumab and denosumab

    Drug: Romosozumab · Drug: Denosumab

  • Active comparator
    Romosozumab

    Drug: Romosozumab

Interventions

06

What researchers measure

Primary outcomes

  1. Total hip areal bone mineral density

    Change in total hip bone density between month 0 and month 12

    Time frame: Month 0 to 12

07

Study locations

1 site
08

References and documents

Publications

  • Leder BZ, Ramchand SK, Jordan M, Ryan S, Patnaik A, Lee H, Tsai JN. 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol. 2026 Mar;14(3):216-222. doi: 10.1016/S2213-8587(25)00319-5. Epub 2026 Jan 29. PubMed 41621431 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Oct 2027, 66 months after the start.

Of 27 phase 4 interventional studies under Osteoporosis, Postmenopausal, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 66. This study's planned 66 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2021
First posted
Aug 18, 2021
StartActual
Mar 24, 2022
Primary completionEst.
Oct 1, 2027
CompletionEst.
Nov 1, 2027
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05010590
Responsible party
Benjamin Leder, MD (Principal Investigator, Massachusetts General Hospital) — Principal investigator
First posted
Aug 18, 2021
Start date
Mar 24, 2022
Primary completion
Oct 1, 2027 (estimated)
Completion
Nov 1, 2027 (estimated)
Last update
Apr 15, 2026

Study contacts

Benjamin Leder, MD
principal investigator · Massachusetts General Hospital

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion